DEF: Endovia Health Sciences Seeks Shareholder Approval for Key Proposals

Endovia Health Sciences is holding a special meeting on December 7, 2026, to vote on proposals including stock issuances, an authorized share increase, and a reverse stock split, crucial for its continued listing and financing.

Summary

• Endovia Health Sciences is convening a Special Meeting of Stockholders on December 7, 2026, to vote on five key proposals.
• These proposals include approving the issuance of shares related to Series D convertible preferred stock and a convertible promissory note, and approving shares issuable under an equity line of credit (ELOC) agreement.
• Stockholders will also vote on increasing the number of authorized common shares to 800,000,000 and approving a reverse stock split with a ratio between 1:2 and 1:49.
• A proposal to adjourn the meeting if necessary to secure sufficient votes is also on the agenda.
• The company's Board of Directors unanimously recommends voting FOR all proposals.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the significant dilution risks, potential for delisting, and the need for multiple shareholder approvals for critical financing and restructuring measures.

Positives

• The company is proactively seeking shareholder approval for measures intended to ensure continued listing on the NYSE American and secure future financing.
• The virtual meeting format is designed to increase stockholder attendance and participation globally.
• The Board of Directors is unanimously recommending approval of all proposals, indicating a unified management stance.

Negatives

• The proposed stock issuances and ELOC agreement carry significant dilution risks for existing shareholders.
• The company is facing potential delisting from the NYSE American due to low stock price and insufficient shareholder equity.
• A reverse stock split is proposed, which historically can be a sign of financial distress and may not guarantee a sustained increase in stock price.
• The company has experienced significant stock price declines throughout 2026.

Risks

• Risk of delisting from the NYSE American if continued listing standards, particularly the minimum bid price and shareholder equity requirements, are not met by January 29, 2027.
• Significant dilution to existing shareholders' equity and voting power due to the proposed issuance of new shares under the Series D, Note, and ELOC agreements.
• The reverse stock split may not be effective in maintaining the stock price above the $0.10 minimum threshold, especially given past performance after a similar split.
• Potential for future delisting if proposed NYSE American rule changes imposing more stringent continued listing requirements (e.g., $5 million market capitalization) take effect.
• The company may be unable to raise sufficient capital through alternative means if the ELOC agreement is not approved, potentially hindering operations and growth.

Future Outlook

The company is seeking shareholder approval for several proposals critical to its ability to raise capital, maintain its stock exchange listing, and fund its operations and growth initiatives. The success of these proposals will directly impact the company's future financial flexibility and operational capacity.

Management Comments

• The Board believes that authorizing the additional shares of common stock is fair to and in the best interests of the Company and its stockholders after taking into account its ongoing needs for capital, compliance with NYSE requirements and the terms of the Convertible Securities.
• The Board believes that, in light of the Company's one-for-four reverse stock split of the Company's outstanding and authorized common stock on July 24, 2026, the Authorized Shares Amendment is necessary to maintain flexibility to issue shares of common stock to raise cash in one or more equity financings to fund our operations, to effect future awards under stockholder-approved equity incentive plans or for other general corporate purposes.
• The Board believes that the Reverse Split is a potentially effective means for us to increase the per share market price of our common stock and to avoid, or at least mitigate, the likely adverse consequences of our common stock being delisted from the NYSE American by producing the immediate effect of increasing the bid price of our common stock.
• The Board unanimously recommends that the stockholders vote FOR each proposal being put before our stockholders at the Special Meeting.

Industry Context

StockSavvy.ai notes that Endovia Health Sciences is operating in a challenging biotech/pharma sector where access to capital is paramount. The company's reliance on equity lines of credit and convertible instruments, coupled with the need for shareholder approval for significant share issuances and restructuring, is common for companies at this stage, particularly those facing listing challenges. Competitors in similar situations often pursue similar capital-raising and restructuring strategies.

Comparison to Industry Standards

• Companies in the biotechnology and pharmaceutical sectors frequently utilize convertible securities and equity lines of credit to finance research, development, and commercialization, especially when traditional debt financing is less accessible.
• The need for shareholder approval for issuances exceeding 20% of outstanding stock is a standard requirement under NYSE American listing rules, aimed at protecting existing shareholders from excessive dilution.
• Reverse stock splits are a common tool employed by companies with low stock prices to meet exchange listing requirements, though their long-term effectiveness in boosting share value is debated and varies by company performance and market perception.
• The focus on maintaining shareholder equity above a minimum threshold (e.g., $6 million for Endovia) is a critical listing requirement for many growth-oriented companies, reflecting investor confidence and financial stability.

Related Party Transactions

• The ELOC Agreement is with C/M Capital Master Fund, LP, an affiliate of C/M Capital Partners, LP, which is also a counterparty to the License Agreement and holder of the convertible promissory note.
• The company is seeking approval for the issuance of shares under the ELOC Agreement, which involves a related party.

Stakeholder Impact

• Existing shareholders face significant dilution of their ownership percentage and voting power due to the proposed share issuances.
• Shareholders risk potential delisting from the NYSE American, which could severely impact the liquidity and value of their investment.
• Employees, consultants, officers, and directors may be impacted by the availability of equity compensation plans, which are dependent on sufficient authorized shares.
• Creditors may be impacted by the company's ability to raise capital and meet its financial obligations, as well as the potential for dilution.

Next Steps

• Stockholders must vote on the five proposals presented at the Special Meeting on December 7, 2026.
• If approved, the company will proceed with increasing authorized shares and potentially effecting a reverse stock split.
• The company must regain compliance with NYSE American continued listing standards by January 29, 2027.
• The company will continue to utilize the ELOC agreement for capital raises as needed, subject to approvals and market conditions.

Key Dates

Recommendation

The company is in a critical phase, seeking shareholder approval for measures to avoid delisting and secure financing. While these actions are necessary, they come with significant dilution risks for existing shareholders. The outcome of the vote and the company's ability to regain listing compliance are key uncertainties. A 'hold' recommendation reflects the balance between the potential for recovery if these measures succeed and the substantial risks involved.

Keywords

Proxy Statement, Special Meeting, Stockholder Approval, Share Issuance, Equity Line of Credit, Reverse Stock Split, Authorized Shares, NYSE American Listing